Psoriasis therapy and cardiovascular risk factors: A 12-week follow-up study

American Journal of Clinical Dermatology

Volumn 11, Issue 6, 2010, Pages 423-432

  Coimbra, Susana ^a,b,c   Oliveira, Hugo ^d   Reis, Flávio ^e   Belo, Luís ^a,b   Rocha, Susana ^a,b   Quintanilha, Alexandre ^a,b   Figueiredo, Américo ^d   Teixeira, Frederico ^e   Castro, Elisabeth ^a,b   Rocha Pereira, Petronila ^b,f   Santos Silva, Alice ^a,b  

^a UNIVERSITY OF PORTO   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c CESPU   (Portugal)

^d CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^e UNIVERSITY OF COIMBRA   (Portugal)

^f UNIVERSITY OF BEIRA INTERIOR   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; BETAMETHASONE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CALCIPOTRIOL; CALCITRIOL; DERMATOLOGICAL AGENT; DRUG DERIVATIVE; GLUCOCORTICOID; LIPID;

ADULT; ARTICLE; BLOOD; CARDIOVASCULAR DISEASE; DRUG EFFECT; FOLLOW UP; HOSPITALIZATION; HUMAN; LIPID METABOLISM; LONGITUDINAL STUDY; MALE; METABOLISM; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; OXIDATIVE STRESS; PHOTOTHERAPY; PSORIASIS; PUVA; RADIATION EXPOSURE; RISK FACTOR;

ADIPONECTIN; ADULT; BETAMETHASONE; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CALCITRIOL; CARDIOVASCULAR DISEASES; COMBINED MODALITY THERAPY; DERMATOLOGIC AGENTS; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; LIPID METABOLISM; LIPIDS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; OXIDATIVE STRESS; PSORIASIS; PUVA THERAPY; RISK FACTORS; SEVERITY OF ILLNESS INDEX; ULTRAVIOLET THERAPY;

EID: 78751684955     PISSN: 11750561     EISSN: 11791888     Source Type: Journal    
DOI: 10.2165/11319310-000000000-00000     Document Type: Article

References (49)

1. Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet 2007; 370: 263-71 (Pubitemid 47069537)
2. Garcia-Diez A, Foraster CF, Sebastian FV, et al. What characterizes the severity of psoriasis? Results from an epidemiological study of over 3300 patients in the Iberian region. Dermatology 2008; 216: 137-51 (Pubitemid 351158579)
3. Ferrandiz C, Bordas X, Garcia-Patos V, et al. Prevalence of psoriasis in Spain (Epiderma Project: phase I). J Eur Acad Dermatol Venereol 2001; 15: 20-3 (Pubitemid 32842768)
4. Vanizor Kural B, Orem A, Cimsit G, et al. Evaluation of the atherogenic tendency of lipids and lipoprotein content and their relationships with oxidant-antioxidant system in patients with psoriasis. Clin Chim Acta 2003; 328: 71-82 (Pubitemid 36135781)
5. Rocha-Pereira P, Santos-Silva A, Rebelo I, et al. Dislipidemia and oxidative stress in mild and in severe psoriasis as a risk for cardiovascular disease. Clin Chim Acta 2001; 303: 33-9 (Pubitemid 32121803)
6. Akhyani M, Ehsani AH, Robati RM, et al. The lipid profile in psoriasis: a controlled study. J Eur Acad Dermatol Venereol 2007; 21: 1330-2 (Pubitemid 350020138)
7. Coimbra S, Oliveira H, Reis F, et al. Circulating levels of adiponectin, oxidized LDL and C-reactive protein in Portuguese patients with psoriasis vulgaris, according to body mass index, severity and duration of the disease. J Derm-atol Sci 2009; 55: 202-4
8. Bajaj DR, Mahesar SM, Devrajani BR, et al. Lipid profile in patients with psoriasis presenting at Liaquat University Hospital Hyderabad. J Pak Med Assoc 2009; 59: 512-5
9. Hashemi M, Daliri M, Mehrabifar H, et al. Lipid profile in patients with psoriasis in Zahedan, south-east Iran. J Eur Acad Dermatol Venereol 2009; 23: 461-2
10. Mallbris L, Larsson P, Bergqvist S, et al. Psoriasis phenotype at disease onset: clinical characterization of 400 adult cases. J Invest Dermatol 2005; 124: 499-504 (Pubitemid 40381571)
11. Sterry W, Strober BE, Menter A. Obesity in psoriasis: the metabolic, clinical and therapeutic implications: report of an interdisciplinary conference and review. Br J Dermatol 2007; 157: 649-55 (Pubitemid 47389868)
12. Clark L, Lebwohl M. The effect of weight on the efficacy of biologic therapy in patients with psoriasis. J Am Acad Dermatol 2008; 58: 443-6
13. Rondinone CM. Adipocyte-derived hormones, cytokines, and mediators. Endocrine 2006; 29: 81-90 (Pubitemid 43780349)
14. Mallika V, Goswami B, Rajappa M. Atherosclerosis pathophysiology and the role of novel risk factors: a clinicobiochemical perspective. Angiology 2007; 58: 513-22 (Pubitemid 47622823)
15. Chapman MJ. Metabolic syndrome and type 2 diabetes: lipid and physiological consequences. Diab Vasc Dis Res 2007; 4 Suppl. 3: S5-8 (Pubitemid 350013470)
16. Takemura Y, Walsh K, Ouchi N. Adiponectin and cardiovascular inflammatory responses. Curr Atheroscler Rep 2007; 9: 238-43 (Pubitemid 47629071)
17. Ahima RS. Adipose tissue as an endocrine organ. Obesity (Silver Spring) 2006; 14 Suppl. 5: 242S-9S
18. Tanaka T, Tsutamoto T, Nishiyama K, et al. Impact of oxidative stress on plasma adiponectin in patients with chronic heart failure. Circ J 2008; 72: 563-8 (Pubitemid 351679407)
19. Takahashi H, Tsuji H, Takahashi I, et al. Plasma adiponectin and leptin levels in Japanese patients with psoriasis. Br J Dermatol 2008; 159: 1207-8
20. Kaur S, Zilmer K, Kairane C, et al. Clear differences in adiponectin level and glutathione redox status revealed in obese and normal-weight patients with psoriasis. Br J Dermatol 2008; 159: 1364-7
21. Shibata S, Saeki H, Tada Y, et al. Serum high molecular weight adiponectin levels are decreased in psoriasis patients. J Dermatol Sci 2009; 55: 62-3
22. Takahashi H, Tsuji H, Takahashi I, et al. Prevalence of obesity/adiposity in Japanese psoriasis patients: adiposity is correlated with the severity of psoriasis. J Dermatol Sci 2009; 55: 74-6
23. Gounopoulos P, MerkiE, Hansen LF, et al. Antibodiesto oxidized low density lipoprotein: epidemiological studies and potential clinical applications in cardiovascular disease. Minerva Cardioangiol 2007; 55: 821-37 (Pubitemid 351169843)
24. Tekin NS, Tekin IO, Barut F, et al. Accumulation of oxidized low-density lipoprotein in psoriatic skin and changes of plasma lipid levels in psoriatic patients. Mediators Inflamm 2007; 2007: 78454
25. Vanizor Kural B, Orem A, Cimsit G, et al. Plasma homocysteine and its relationships with atherothrombotic markers in psoriatic patients. Clin Chim Acta 2003; 332: 23-30 (Pubitemid 36577485)
26. Takahashi H, Tsuji H, Takahashi I, et al. Plasma adiponectin and leptin levels in Japanese patients with psoriasis. Br J Dermatol 2008 Nov; 159 (5): 1207-8
27. Strober B, Teller C, Yamauchi P, et al. Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis. Br J Dermatol 2008; 159: 322-30 (Pubitemid 352009830)
28. Chodorowska G, Wojnowska D, Juszkiewicz-Borowiec M. C-reactive protein and alpha2-macroglobulin plasma activity in medium-severe and severe psoriasis. J Eur Acad Dermatol Venereol 2004; 18: 180-3 (Pubitemid 38379896)
29. Biljan D, Situm M, Kostovic K, et al. Acute phase proteins in psoriasis. Coll Antropol 2009; 33: 83-6
30. Corbetta S, Angioni R, Cattaneo A, et al. Effects of retinoid therapy on insulin sensitivity, lipid profile and circulating adipocytokines. Eur J Endocrinol 2006; 154: 83-6 (Pubitemid 43250740)
31. Chodorowska G, Juszkiewicz-Borowiec M, Czelej D, et al. Activity of tumor necrosis factor-alfa (TNF-alpha) and selected acute phase proteins in plasma of psoriatic patients receiving local treatment. Ann Univ Mariae Curie Sklodowska Med 2001; 56: 165-9
32. Naldi L, Griffiths CE. Traditional therapies in the management of moderate to severe chronic plaque psoriasis: an assessment of the benefits and risks. Br J Dermatol 2005; 152: 597-615 (Pubitemid 40571289)
33. Fredriksson T, Pettersson U. Severe psoriasis: oral therapy with a new retinoid. Dermatologica 1978; 157: 238-44 (Pubitemid 8387357)
34. Niehaus Jr WG, Samuelsson B. Formation of malonaldehyde from phospholipid arachidonate during microsomal lipid peroxidation. Eur J Biochem 1968; 6: 126-30
35. Uyanik BS, Ari Z, Onur E, et al. Serum lipids and apolipoproteins in patients with psoriasis. Clin Chem Lab Med 2002; 40: 65-8 (Pubitemid 34196452)
36. Reynoso-von Drateln C, Martinez-Abundis E, Balcazar-Munoz BR, et al. Lipid profile, insulin secretion, and insulin sensitivity in psoriasis. J Am Acad Dermatol 2003; 48: 882-5 (Pubitemid 36706221)
37. Piskin S, Gurkok F, Ekuklu G, et al. Serum lipid levelsinpsoriasis. YonseiMed J 2003; 44: 24-6
38. Farshchian M, Zamanian A, Farshchian M, et al. Serum lipid level in Iranian patients with psoriasis. J Eur Acad Dermatol Venereol 2007; 21: 802-5 (Pubitemid 46939054)
39. Pietrzak A, Lecewicz-Torun B. Activity of serum lipase [EC 3.1.1.3] and the diversity of serum lipid profile in psoriasis. Med Sci Monit 2002; 8: CR9-13
40. Franz H, Wendler D. A controlled study of maternal serum concentrations of lipoproteins in pregnancy-induced hypertension. Arch Gynecol Obstet 1992; 252: 81-6
41. Mallbris L, Granath F, Hamsten A, et al. Psoriasis is associated with lipid abnormalities at the onset of skin disease. J Am Acad Dermatol 2006; 54: 614-21
42. Willerson JT, Ridker PM. Inflammation as a cardiovascular risk factor. Circulation 2004; 109: II2-10
43. Pietrzak A, Kadzielewski J, Janowski K, et al. Lipoprotein (a) in patients with psoriasis: associations with lipid profiles and disease severity. Int J Dermatol 2009; 48: 379-87
44. Anuurad E, Boffa MB, Koschinsky ML, et al. Lipoprotein(a): a unique risk factor for cardiovascular disease. Clin Lab Med 2006; 26: 751-72 (Pubitemid 44716507)
45. Merki E, Graham MJ, Mullick AE, et al. Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice. Circulation 2008; 118: 743-53
46. dos Santos DJ, Eriksson LA. Permeability of psoralen derivatives in lipid membranes. Biophys J 2006; 91: 2464-74 (Pubitemid 44511702)
47. Trenkwalder E, Gruber A, Konig P, et al. Increased plasma concentrations of LDL-unbound apo(a) in patients with end-stage renal disease. Kidney Int 1997; 52: 1685-92 (Pubitemid 28032076)
48. Rocha-Pereira P, Santos-Silva A, Rebelo I, et al. The inflammatory response in mild and in severe psoriasis. Br J Dermatol 2004; 150: 917-28 (Pubitemid 38903524)
49. Coimbra S, Oliveira H, Reis F, et al. C-reactive protein and leucocyte activation in psoriasis vulgaris according to severity and therapy. J Eur Acad Dermatol Venereol. Epub ahead of print